Intellia Therapeutics, Inc. Fair Value Disclosure

4. Fair Value Measurements

The Company classifies fair value-based measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1, quoted market prices (unadjusted) in active markets for identical assets or liabilities; Level 2, observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data; and Level 3, unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Certain of the Company’s financial assets, including cash equivalents, restricted cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.

Other financial instruments, including accounts receivable, accounts payable and accrued expense, are carried at cost, which approximates fair value due to the short duration and term to maturity.

The Company has determined that the estimated fair value of its investment in Kyverna Therapeutics, Inc. (“Kyverna”), a publicly traded company, is reported as Level 1 as it is valued at a quoted market price in an active market. The investment in Kyverna is classified within “Investments and other assets” in the consolidated balance sheets. Refer to Note 10, “Investments and Other Assets,” for further details.

Other Investments

SparingVision SAS

The Company’s investment in SparingVision was initially recorded at fair value, determined according to Level 3 inputs in the fair value hierarchy described above. The SparingVision investment is included in “Investments and other assets” on the consolidated balance sheets and is accounted for using the measurement alternative at cost minus impairment, adjusted for

changes in observable prices. In October 2025, the Company executed a termination agreement with SparingVision, triggering a qualitative assessment of the Company’s investment which was determined to be impaired. The Company determined the fair value of the SparingVision investment to be approximately $7.1 million using an option pricing model which requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are Level 3 inputs, include the anticipated holding period to an exit and liquidity event, the indicated equity volatility (80%), and the risk free rate (2.2%). This resulted in the recognition of a $7.5 million loss recorded within “Change in fair value of investments, net” of the Company’s consolidated statement of operations and comprehensive loss. In connection with the termination, the Company returned 50% of its investment to SparingVision, which was determined to have a value of $3.6 million. As of December 31, 2025 and 2024, the carrying value of the SparingVision investment was $3.5 million and $14.6 million, respectively. Refer to Note 10, “Investments and Other Assets” for further details.

AvenCell Therapeutics, Inc.

The Company’s investment in AvenCell is recorded at fair value, determined according to Level 3 inputs in the fair value hierarchy described above. This investment is accounted for using the measurement alternative at cost minus impairment, adjusted for changes in observable prices. The AvenCell investment is included in “Investments and other assets” on the consolidated balance sheet as of December 31, 2025. The Company previously accounted for the AvenCell investment under the equity method; refer to Note 10, “Investments and Other Assets,” for further details including the change in fair value.

In the fourth quarter of 2024, AvenCell completed a Series B financing, which represented an observable price change in the Company’s investment in AvenCell. The Company determined the fair value of the AvenCell investment using an option pricing model which requires the input of certain subjective assumptions. The key assumptions used in the option pricing model, which are Level 3 inputs, include the anticipated holding period to an exit and liquidity event, the indicated equity volatility (95%), and the risk free rate (3.9%). The carrying value of the Company’s investment in AvenCell was $7.9 million as of December 31, 2025 and 2024.

Contingent Consideration

In February 2022, the Company entered into an Agreement and Plan of Merger by and among the Company, Rewrite, RW Acquisition Corp. and Shareholder Representative Services, LLC as Securityholder representative (the “Rewrite Merger Agreement”), which was accounted for as an asset acquisition. Under the Rewrite Merger Agreement, and as of December 31, 2025, the Company Securityholders (as defined in the Rewrite Merger Agreement) (the “Rewrite Holders”) are eligible to receive up to an additional $130.0 million, including $100.0 million upon the achievement of a regulatory approval milestone and $30.0 million upon achievement of pre-specified research milestones, payable in cash. The remaining contingent milestones are subject to cash settlement upon achievement. The Company accounts for contingent consideration identified in an asset acquisition, that is payable in cash, when the contingency is resolved and the consideration is paid or becomes payable. As of December 31, 2025 and December 31, 2024, no liability has been recorded.